LT5064B - Avies pararaupų viruso kamienai, skirti panaudoti prieš organų fibrozę - Google Patents
Avies pararaupų viruso kamienai, skirti panaudoti prieš organų fibrozę Download PDFInfo
- Publication number
- LT5064B LT5064B LT2003008A LT2003008A LT5064B LT 5064 B LT5064 B LT 5064B LT 2003008 A LT2003008 A LT 2003008A LT 2003008 A LT2003008 A LT 2003008A LT 5064 B LT5064 B LT 5064B
- Authority
- LT
- Lithuania
- Prior art keywords
- fibrosis
- preventive
- manufacture
- curative effect
- human
- Prior art date
Links
- 210000000056 organ Anatomy 0.000 title claims abstract description 9
- 206010016654 Fibrosis Diseases 0.000 title claims description 23
- 230000004761 fibrosis Effects 0.000 title claims description 20
- 241000700605 Viruses Species 0.000 title claims description 19
- 241000283898 Ovis Species 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 21
- 241000700639 Parapoxvirus Species 0.000 claims abstract description 19
- 238000004519 manufacturing process Methods 0.000 claims abstract description 16
- 210000004027 cell Anatomy 0.000 claims description 18
- 230000009982 effect on human Effects 0.000 claims description 14
- 230000003449 preventive effect Effects 0.000 claims description 14
- 230000003510 anti-fibrotic effect Effects 0.000 claims description 11
- 241000700665 Sheeppox virus Species 0.000 claims description 10
- 239000012634 fragment Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 238000004113 cell culture Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 230000006978 adaptation Effects 0.000 claims description 4
- 241001494479 Pecora Species 0.000 claims description 3
- 108091027544 Subgenomic mRNA Proteins 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 claims description 3
- 210000002950 fibroblast Anatomy 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 239000013598 vector Substances 0.000 claims description 3
- 238000011156 evaluation Methods 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 2
- 244000309464 bull Species 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 10
- 238000011282 treatment Methods 0.000 abstract description 6
- 238000011321 prophylaxis Methods 0.000 abstract description 4
- 201000003883 Cystic fibrosis Diseases 0.000 abstract description 2
- 206010019799 Hepatitis viral Diseases 0.000 abstract description 2
- 208000019423 liver disease Diseases 0.000 abstract description 2
- 201000001862 viral hepatitis Diseases 0.000 abstract description 2
- 241001465754 Metazoa Species 0.000 description 36
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 32
- 210000004185 liver Anatomy 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 19
- 239000002775 capsule Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 102000008186 Collagen Human genes 0.000 description 11
- 108010035532 Collagen Proteins 0.000 description 11
- 229920001436 collagen Polymers 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 239000008215 water for injection Substances 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 210000004051 gastric juice Anatomy 0.000 description 7
- 230000009466 transformation Effects 0.000 description 7
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 6
- 108010082126 Alanine transaminase Proteins 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 6
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 6
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 6
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 6
- 101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 description 6
- 102000016901 Glutamate dehydrogenase Human genes 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000003995 blood forming stem cell Anatomy 0.000 description 5
- 230000007882 cirrhosis Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 4
- 229940087168 alpha tocopherol Drugs 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229960000984 tocofersolan Drugs 0.000 description 4
- 239000002076 α-tocopherol Substances 0.000 description 4
- 235000004835 α-tocopherol Nutrition 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 230000003352 fibrogenic effect Effects 0.000 description 3
- 230000003176 fibrotic effect Effects 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 208000001378 Carbon Tetrachloride Poisoning Diseases 0.000 description 2
- 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- YIQKLZYTHXTDDT-UHFFFAOYSA-H Sirius red F3B Chemical compound C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3[O-])NC(=O)NC5=CC6=CC(=C(C(=C6C=C5)[O-])N=NC7=C(C=C(C=C7)N=NC8=CC=C(C=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] YIQKLZYTHXTDDT-UHFFFAOYSA-H 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000013245 carbon tetrachloride model Methods 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 210000001728 clone cell Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 210000004738 parenchymal cell Anatomy 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 1
- CRCWUBLTFGOMDD-UHFFFAOYSA-N 7-ethoxyresorufin Chemical compound C1=CC(=O)C=C2OC3=CC(OCC)=CC=C3N=C21 CRCWUBLTFGOMDD-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 1
- -1 GGT Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010002885 Polygeline Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- FXAGBTBXSJBNMD-UHFFFAOYSA-N acetic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O FXAGBTBXSJBNMD-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000569 acute exposure Toxicity 0.000 description 1
- 231100000439 acute liver injury Toxicity 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 201000005332 contagious pustular dermatitis Diseases 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 210000000208 hepatic perisinusoidal cell Anatomy 0.000 description 1
- 210000004024 hepatic stellate cell Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229960004250 polygeline Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- BXSDMMPOQRECKB-UHFFFAOYSA-N sodium;chloro-(4-methylphenyl)sulfonylazanide;hydrate Chemical compound O.[Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 BXSDMMPOQRECKB-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24211—Parapoxvirus, e.g. Orf virus
- C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10033581 | 2000-07-11 | ||
| DE10122233A DE10122233A1 (de) | 2000-07-11 | 2001-05-08 | Verwendung von Stämmen des Parapoxvirus ovis gegen Organfibrosen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LT2003008A LT2003008A (en) | 2003-07-25 |
| LT5064B true LT5064B (lt) | 2003-11-25 |
Family
ID=26006334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LT2003008A LT5064B (lt) | 2000-07-11 | 2003-02-03 | Avies pararaupų viruso kamienai, skirti panaudoti prieš organų fibrozę |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6632647B2 (sk) |
| EP (1) | EP1303302B1 (sk) |
| JP (1) | JP5106736B2 (sk) |
| CN (1) | CN1452496B (sk) |
| AR (1) | AR028800A1 (sk) |
| AU (2) | AU8582701A (sk) |
| BG (1) | BG107447A (sk) |
| CA (1) | CA2415399C (sk) |
| CZ (1) | CZ200372A3 (sk) |
| DK (1) | DK200300014A (sk) |
| EE (1) | EE200300019A (sk) |
| FI (1) | FI20030038A (sk) |
| GB (1) | GB2383752B (sk) |
| HK (1) | HK1054330B (sk) |
| HR (1) | HRP20030097A2 (sk) |
| HU (1) | HU227668B1 (sk) |
| IL (1) | IL153826A0 (sk) |
| LT (1) | LT5064B (sk) |
| LU (1) | LU90996B1 (sk) |
| LV (1) | LV12991B (sk) |
| MA (1) | MA25765A1 (sk) |
| MX (1) | MXPA03000278A (sk) |
| NO (1) | NO20030081D0 (sk) |
| NZ (1) | NZ523535A (sk) |
| PL (1) | PL360839A1 (sk) |
| RU (1) | RU2003104522A (sk) |
| SE (1) | SE0300033L (sk) |
| SI (1) | SI21171A (sk) |
| SK (1) | SK382003A3 (sk) |
| WO (1) | WO2002004019A2 (sk) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19922407A1 (de) * | 1999-05-14 | 2000-11-16 | Bayer Ag | Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus |
| AU2002362072A1 (en) | 2001-12-07 | 2003-06-23 | Board Of Regents The University Of Texas System | Use a parapox b2l protein to modify immune responses to administered antigens |
| US6752995B2 (en) | 2002-04-15 | 2004-06-22 | Board Of Regents, The University Of Texas System | Nucleic acid and polypeptide sequences useful as adjuvants |
| EP1574211A1 (en) | 2004-03-09 | 2005-09-14 | Inserm | Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases |
| WO2012045473A1 (en) * | 2010-10-07 | 2012-04-12 | Technische Universität München | Viruses for the treatment of fibrosis |
| US11077157B2 (en) | 2016-02-16 | 2021-08-03 | Osaka University | Medicinal composition for treating fibrosis |
| TW201919675A (zh) * | 2017-09-07 | 2019-06-01 | 德商艾庫瑞斯公司 | 使用羊副痘疹病毒(Parapoxvirus ovis；PPVO)及至少一種額外抗病毒藥之經B型肝炎病毒(HBV)感染之個體之組合療法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3504940A1 (de) | 1984-02-17 | 1985-10-31 | Mayr, Anton, Prof. Dr.med.vet. Dr.h.c.mult., 8000 München | Multipotente paramunitaetsmediatoren, verfahren zu ihrer herstellung und diese mediatoren enthaltende arzneimittel |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2714665A1 (de) * | 1977-04-01 | 1978-10-05 | Mayr Anton | Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung |
| US4360510A (en) * | 1979-11-30 | 1982-11-23 | Proctor Julian W | Method for screening anti-tumor agents of the reticulo-endothelial stimulant class |
| US4663306A (en) * | 1983-09-23 | 1987-05-05 | Ribi Immunochem Research, Inc. | Pyridine-soluble extract-refined detoxified endotoxin composition and use |
| DE3816139A1 (de) * | 1987-10-17 | 1989-04-27 | Bayer Ag | Verfahren zur herstellung von paramunitaetsinducern |
| DE4405841C1 (de) * | 1994-02-23 | 1995-01-05 | Mayr Anton Prof Dr Med Vet Dr | Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| KR100302994B1 (ko) * | 1996-04-15 | 2001-11-30 | 안톤 마이어 | 약독화된비면역원성폭스바이러스또는파라폭스바이러스로부터멀티포텐트파라폭스면역유발인자의약제로서이용하는새로운적용 |
| DE19922407A1 (de) * | 1999-05-14 | 2000-11-16 | Bayer Ag | Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus |
| IL139593A (en) * | 2000-11-09 | 2010-12-30 | Biogem Optical Ltd | Method for the detection of viable microorganisms |
-
2001
- 2001-07-11 US US09/903,005 patent/US6632647B2/en not_active Expired - Lifetime
- 2001-07-11 EE EEP200300019A patent/EE200300019A/xx unknown
- 2001-07-11 CA CA2415399A patent/CA2415399C/en not_active Expired - Lifetime
- 2001-07-11 HU HU0303830A patent/HU227668B1/hu not_active IP Right Cessation
- 2001-07-11 JP JP2002508473A patent/JP5106736B2/ja not_active Expired - Lifetime
- 2001-07-11 LU LU90996A patent/LU90996B1/en active
- 2001-07-11 NZ NZ52353501A patent/NZ523535A/xx unknown
- 2001-07-11 IL IL15382601A patent/IL153826A0/xx active IP Right Grant
- 2001-07-11 EP EP01965110A patent/EP1303302B1/de not_active Expired - Lifetime
- 2001-07-11 SK SK38-2003A patent/SK382003A3/sk not_active Application Discontinuation
- 2001-07-11 WO PCT/EP2001/007978 patent/WO2002004019A2/de active IP Right Grant
- 2001-07-11 AU AU8582701A patent/AU8582701A/xx active Pending
- 2001-07-11 AR ARP010103291A patent/AR028800A1/es not_active Application Discontinuation
- 2001-07-11 PL PL36083901A patent/PL360839A1/xx not_active Application Discontinuation
- 2001-07-11 AU AU2001285827A patent/AU2001285827B2/en not_active Expired
- 2001-07-11 GB GB0302629A patent/GB2383752B/en not_active Expired - Lifetime
- 2001-07-11 CN CN018151272A patent/CN1452496B/zh not_active Expired - Lifetime
- 2001-07-11 SI SI200120047A patent/SI21171A/sl not_active IP Right Cessation
- 2001-07-11 RU RU2003104522/15A patent/RU2003104522A/ru not_active Application Discontinuation
- 2001-07-11 CZ CZ200372A patent/CZ200372A3/cs unknown
- 2001-07-11 MX MXPA03000278A patent/MXPA03000278A/es active IP Right Grant
-
2003
- 2003-01-08 NO NO20030081A patent/NO20030081D0/no not_active Application Discontinuation
- 2003-01-08 BG BG107447A patent/BG107447A/bg unknown
- 2003-01-10 SE SE0300033A patent/SE0300033L/xx not_active Application Discontinuation
- 2003-01-10 DK DK200300014A patent/DK200300014A/da not_active Application Discontinuation
- 2003-01-10 MA MA26995A patent/MA25765A1/fr unknown
- 2003-01-10 FI FI20030038A patent/FI20030038A/fi not_active IP Right Cessation
- 2003-02-03 LT LT2003008A patent/LT5064B/lt not_active IP Right Cessation
- 2003-02-10 HR HR20030097A patent/HRP20030097A2/xx not_active Application Discontinuation
- 2003-02-11 LV LVP-03-13A patent/LV12991B/lv unknown
- 2003-09-15 HK HK03106614.0A patent/HK1054330B/zh not_active IP Right Cessation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3504940A1 (de) | 1984-02-17 | 1985-10-31 | Mayr, Anton, Prof. Dr.med.vet. Dr.h.c.mult., 8000 München | Multipotente paramunitaetsmediatoren, verfahren zu ihrer herstellung und diese mediatoren enthaltende arzneimittel |
Non-Patent Citations (3)
| Title |
|---|
| BHUNCHET E, WAKE K.: "Role of mesenchymal cell populations in porcine serum-induced rat liver fibrosis", HEPATOLOGY, 1992, pages 1452 - 1473 |
| JOHNSON, S. J., HINES, J. E., BURT, A. D.: "Phenotypic modulation of perisinusoidal cells following acute liver injury: a quantitative analysis", INT. J. EXP. PATH., 1992, pages 765 - 772 |
| MCLEAN EK, MCLEAN AE, SUTTON PM.: "Instant cirrhosis. An improved method for producing cirrhosis of the liver in rats by simultaneous administration of carbon tetrachloride and phenobarbitone", BR J EXP PATHOL., 1969, pages 502 - 506 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yoon et al. | An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma | |
| RU2461630C2 (ru) | Применение комбинации вируса миксомы и рапамицина для терапевтического лечения | |
| JP2011157399A (ja) | 癌および慢性ウイルス感染の治療処置のための粘液腫症ウイルスの使用 | |
| Bennett et al. | Studies on poxvirus infection in cats | |
| LT5064B (lt) | Avies pararaupų viruso kamienai, skirti panaudoti prieš organų fibrozę | |
| JP5950964B2 (ja) | 臓器線維形成に対するパラポックスウイルスｏｖｉｓ株の使用 | |
| EP1578959A1 (en) | Immunizing fish against viral infection | |
| Garza et al. | Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE® against aerosolized rabbitpox virus in a rabbit model | |
| US20160136212A1 (en) | Myxoma virus mutants for cancer treatment | |
| Tonew et al. | Replication and persistence of coxsackieviruses B3 in human fibroblasts | |
| CN112472791A (zh) | CsA脂质体在制备抗SARS-CoV-2药物中的应用 | |
| CN116211865B (zh) | 一种化合物Ibrutinib在制备抗病毒药物中的应用、药物组合物 | |
| US11591616B1 (en) | Apoptotic upregulation by myxoma virus expressing walleye dermal sarcoma virus orfC | |
| Weissenbacher et al. | Sensitivity of human conjunctival tissue cultures to adenovirus 8, herpes simplex and vaccinia viruses. Induction of resistance by an interferon inducer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC9A | Transfer of patents |
Owner name: AICURIS GMBH & CO. KG, DE Effective date: 20060824 |
|
| MM9A | Lapsed patents |
Effective date: 20140711 |